Hhlr Advisors, Ltd. Blueprint Medicines Corp Transaction History

Hhlr Advisors, Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $51.4 Million - $69.5 Million	-635,302 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$82.78 - $101.0 $10.2 Million - $12.5 Million	-123,389 Reduced 16.26%	635,302 $55.9 Million
Q1 2021 May 17, 2021	SELL	$90.71 - $108.28 $46.4 Million - $55.4 Million	-511,838 Reduced 40.29%	758,691 $73.8 Million
Q4 2020 Feb 12, 2021	SELL	$92.08 - $124.48 $8.66 Million - $11.7 Million	-94,102 Reduced 6.9%	1,270,529 $142 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $14.2 Million - $19.7 Million	-248,663 Reduced 15.41%	1,364,631 $106 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $5.23 Million - $8.94 Million	108,695 Added 7.22%	1,613,294 $94.3 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $405,918 - $502,394	6,083 Added 0.41%	1,504,599 $121 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $3.29 Million - $5.85 Million	67,567 Added 4.72%	1,498,516 $120 Million
Q4 2018 Feb 14, 2019	BUY	$45.57 - $74.26 $65.2 Million - $106 Million	1,430,949 New	1,430,949 $77.1 Million

380

65.9M

1.6M

1.41M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.18B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.